# Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

> **NCT01177098** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 561 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** bimatoprost /timolol formulation A fixed combination ophthalmic solution
- **DRUG:** bimatoprost/timolol fixed combination ophthalmic solution

## Key facts

- **NCT ID:** NCT01177098
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 561 (ACTUAL)
- **Last updated:** 2013-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177098, "Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01177098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*